Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.41 |
| ▸ | F10 | P00742 | 7/20 | 0.38 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14062797 | 0.88 | IRAK4 (0.43) | IRAK4F10F2KLKB1NPSR1 | |
| SCHEMBL5064356 | 0.81 | OPRM1 (0.39) | IRAK4F10ABL1SRC | |
| SCHEMBL5066931 | 0.80 | IRAK4 (0.36) | IRAK4F10 | |
| SCHEMBL14012647 | 0.80 | CARM1 (0.46) | IRAK4 | |
| SCHEMBL5070493 | 0.78 | IRAK4 (0.35) | IRAK4F10 | |
| SCHEMBL5067650 | 0.76 | EPHX2 (0.40) | — | |
| SCHEMBL5067006 | 0.76 | IRAK4 (0.37) | IRAK4F10NPSR1L3MBTL1 | |
| SCHEMBL5066912 | 0.76 | CARM1 (0.45) | IRAK4 | |
| SCHEMBL5066914 | 0.76 | CARM1 (0.45) | IRAK4 | |
| SCHEMBL5067010 | 0.76 | RXFP1 (0.40) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | IRAK4 4200/4885F10 4114/4885ABL1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.